Literature DB >> 21651941

Vaccine stabilization: research, commercialization, and potential impact.

Debra Kristensen1, Dexiang Chen, Ray Cummings.   

Abstract

All vaccines are susceptible to damage by elevated temperatures and many are also damaged by freezing. The distribution, storage, and use of vaccines therefore present challenges that could be reduced by enhanced thermostability, with resulting improvements in vaccine effectiveness. Formulation and processing technologies exist that can improve the stability of vaccines at temperature extremes, however, customization is required for individual vaccines and results are variable. Considerations affecting decisions about stabilization approaches include development cost, manufacturing cost, and the ease of use of the final product. Public sector agencies can incentivize vaccine developers to prioritize stabilization efforts through advocacy and by implementing policies that increase demand for thermostable vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21651941     DOI: 10.1016/j.vaccine.2011.05.070

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment.

Authors:  Sameer Kumar Malladi; Randhir Singh; Suman Pandey; Savitha Gayathri; Kawkab Kanjo; Shahbaz Ahmed; Mohammad Suhail Khan; Parismita Kalita; Nidhi Girish; Aditya Upadhyaya; Poorvi Reddy; Ishika Pramanick; Munmun Bhasin; Shailendra Mani; Sankar Bhattacharyya; Jeswin Joseph; Karthika Thankamani; V Stalin Raj; Somnath Dutta; Ramandeep Singh; Gautham Nadig; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2020-11-23       Impact factor: 5.157

2.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

3.  Development of a highly thermostable, adjuvanted human papillomavirus vaccine.

Authors:  Kimberly J Hassett; Natalie M Meinerz; Florian Semmelmann; Megan C Cousins; Robert L Garcea; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2015-05-18       Impact factor: 5.571

4.  Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up.

Authors:  Changcheng Zhu; Yoko Shoji; Scott McCray; Michael Burke; Caitlin E Hartman; Jessica A Chichester; Jeff Breit; Vidadi Yusibov; Dexiang Chen; Manjari Lal
Journal:  Pharm Res       Date:  2014-05-24       Impact factor: 4.200

5.  A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.

Authors:  Xinran Li; Sachin G Thakkar; Tinashe B Ruwona; Robert O Williams; Zhengrong Cui
Journal:  J Control Release       Date:  2015-02-28       Impact factor: 9.776

Review 6.  Supramolecular peptide vaccines: tuning adaptive immunity.

Authors:  Yi Wen; Joel H Collier
Journal:  Curr Opin Immunol       Date:  2015-07-08       Impact factor: 7.486

7.  The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different temperatures.

Authors:  Sachin G Thakkar; Tinashe B Ruwona; Robert O Williams; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2017-01-04       Impact factor: 3.452

8.  Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.

Authors:  Carly Fleagle Chisholm; Taek Jin Kang; Miao Dong; Kasey Lewis; Madhuri Namekar; Axel T Lehrer; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2019-01-28       Impact factor: 5.571

9.  Long-term stability of a vaccine formulated with the amphipol-trapped major outer membrane protein from Chlamydia trachomatis.

Authors:  H Eric Feinstein; Delia Tifrea; Guifeng Sun; Jean-Luc Popot; Luis M de la Maza; Melanie J Cocco
Journal:  J Membr Biol       Date:  2014-06-19       Impact factor: 1.843

10.  Modular Peptide Amphiphile Micelles Improving an Antibody-Mediated Immune Response to Group A Streptococcus.

Authors:  John C Barrett; Bret D Ulery; Amanda Trent; Simon Liang; Natalie A David; Matthew V Tirrell
Journal:  ACS Biomater Sci Eng       Date:  2016-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.